论文部分内容阅读
已有研究证明硫氧还蛋白还原酶在多种人原发肿瘤中过度表达,其活性在肿瘤人群和健康人群中有明显差异。本文研究了健康人群和乳腺癌患者中TrxR活性的不同,并探讨了硫氧还蛋白还原酶作为乳腺癌治疗中的一个新型治疗靶点的可能性。通过研究,我们第一次发现未经治疗的肿瘤患者的TrxR活性值水平明显高于健康人群。在乳腺癌患者中,TrxR活性值在不同的年龄组和癌症分期组没有明显的差异。当TrxR活性值小于10 U/mL时,TrxR活性值和肿瘤影像学评价结果有很高的一致性。这些发现证明硫氧还蛋白还原酶可以作为一个有效的新型生物标志物用于对乳腺癌临床治疗效果的监测和评价,并能成为乳腺癌早期检测的一种方法。
Studies have shown that thioredoxin reductase is overexpressed in a variety of human primary tumors and its activity is significantly different between cancer and healthy individuals. This article examines the differences in TrxR activity in healthy individuals and breast cancer patients and explores the potential of thioredoxin reductase as a novel therapeutic target in the treatment of breast cancer. For the first time, we found that the level of TrxR activity in untreated cancer patients was significantly higher than that in healthy people. In breast cancer patients, TrxR activity values in different age groups and cancer staging group no significant difference. When the TrxR activity value is less than 10 U / mL, the TrxR activity value is highly consistent with the tumor imaging evaluation results. These findings demonstrate that thioredoxin reductase can be used as an effective new biomarker for the monitoring and evaluation of the clinical efficacy of breast cancer and as a method of early detection of breast cancer.